FibroGen to Join Upcoming Investor Conferences

FibroGen, Inc., a biopharmaceutical company headquartered in San Francisco, announced their participation in upcoming investor conferences. The company's management will engage in one-on-one investor meetings at the Bank of America Health Care Conference on May 14, 2024, in Las Vegas, NV. Additionally, they will attend the H.C. Wainwright 2nd Annual Bioconnect Investor Conference on May 20, 2024, in New York, NY. At this event, they will host a Fireside Chat from 5:00 to 5:30 PM ET, which will be available via a live audio webcast on FibroGen's Investor webpage and can be replayed for 30 days.

FibroGen is dedicated to the development of innovative therapies in cancer biology. It is progressing with pamrevlumab, an anti-CTGF monoclonal antibody, for treating metastatic and locally advanced unresectable pancreatic cancer. Another significant product, roxadustat, is approved in several regions including China, Europe, and Japan, for treating anemia in chronic kidney disease patients. Roxadustat is also being evaluated for chemotherapy-induced anemia, with a Supplemental New Drug Application under review by the China Health Authority.

Additionally, the company is working on FG-3246 (FOR46), an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer, which includes the development of a related CD46-targeted PET biomarker. FibroGen's research portfolio has expanded to include two immuno-oncology candidates aimed at treating solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!